On-Clamp vs. Off-Clamp Robot-Assisted Partial Nephrectomy for cT2 Renal Tumors: Retrospective Propensity-Score-Matched Multicenter Outcome Analysis.

clinical T2 hilar clamping off-clamp on-clamp outcomes partial nephrectomy renal mass renal neoplasm robot-assisted

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
13 Sep 2022
Historique:
received: 20 07 2022
revised: 30 08 2022
accepted: 03 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

We compared perioperative outcomes after on-clamp versus off-clamp robot-assisted partial nephrectomy (RAPN) for >7 cm renal masses. A multicenter dataset was queried for patients who had undergone RAPN for a cT2cN0cM0 kidney tumor from July 2007 to February 2022. The Trifecta achievement (negative surgical margins, no severe complications, and ≤ 30% postoperative estimated glomerular filtration rate (eGFR) reduction) was considered a surrogate of surgical quality. Overall, 316 cases were included in the analysis, and 58% achieved the Trifecta. A propensity-score-matched analysis generated two cohorts of 89 patients homogeneous for age, ASA score, preoperative eGFR, and RENAL score (all p > 0.21). Compared to the on-clamp approach, OT was significantly shorter in the off-clamp group (80 vs. 190 min; p < 0.001), the incidence of sRFD was lower (22% vs. 40%; p = 0.01), and the Trifecta rate higher (66% vs. 46%; p = 0.01). In a crude analysis, >20 min of hilar clamping was associated with a significantly higher risk of sRFD (OR: 2.30; 95%CI: 1.13−4.64; p = 0.02) and with reduced probabilities of achieving the Trifecta (OR: 0.46; 95%CI: 0.27−0.79; p = 0.004). Purely off-clamp RAPN seems to be a safe and viable option to treat cT2 renal masses and may outperform the on-clamp approach regarding perioperative surgical outcomes.

Identifiants

pubmed: 36139591
pii: cancers14184431
doi: 10.3390/cancers14184431
pmc: PMC9496892
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Am J Kidney Dis. 2003 Jan;41(1):1-12
pubmed: 12500213
Minerva Urol Nefrol. 2020 Aug;72(4):482-489
pubmed: 32298069
J Urol. 2020 Mar;203(3):496-504
pubmed: 31609167
J Urol. 2007 Feb;177(2):471-6
pubmed: 17222613
Eur Urol. 2014 Oct;66(4):713-9
pubmed: 24486306
PLoS One. 2018 May 3;13(5):e0196427
pubmed: 29723225
Urology. 2014 Sep;84(3):602-8
pubmed: 24929947
Eur Urol. 2018 Aug;74(2):226-232
pubmed: 29784191
Urology. 2009 Jun;73(6):1300-5
pubmed: 19376568
Eur Urol. 2018 Apr;73(4):560-569
pubmed: 29325693
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
J Urol. 2015 Jun;193(6):1889-98
pubmed: 25637858
Eur Urol. 2011 Apr;59(4):543-52
pubmed: 21186077
Eur J Surg Oncol. 2019 Jul;45(7):1232-1237
pubmed: 30553632
BJU Int. 2007 Dec;100(6):1235-9
pubmed: 17979923
BJU Int. 2014 Nov;114(5):741-7
pubmed: 24690155
BJU Int. 2019 Apr;123(4):639-645
pubmed: 30253020
Urology. 2015 Aug;86(2):312-9
pubmed: 26189330
J Urol. 2018 Oct;200(4):716-730
pubmed: 29730203
World J Urol. 2017 May;35(5):781-787
pubmed: 27663423
Eur Urol Focus. 2019 Jul;5(4):619-635
pubmed: 29422419
J Endourol. 2011 Sep;25(9):1443-6
pubmed: 21797763
Eur Urol. 2011 Aug;60(2):241-8
pubmed: 21458155
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
BJU Int. 2020 Jul;126(1):114-123
pubmed: 32232920
Eur Urol. 2010 Oct;58(4):588-95
pubmed: 20674150
Eur Urol. 2015 Oct;68(4):632-40
pubmed: 25922273
Eur Urol. 2017 Apr;71(4):606-617
pubmed: 27614693
Minerva Urol Nefrol. 2020 Feb;72(1):82-90
pubmed: 31833720
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Urol. 2018 Aug;200(2):258-274
pubmed: 29580709
Eur Urol. 2016 Apr;69(4):745-752
pubmed: 26525838
J Robot Surg. 2017 Jun;11(2):223-229
pubmed: 27804062
J Urol. 2010 Mar;183(3):903-8
pubmed: 20083271
Am J Kidney Dis. 2014 Dec;64(6):821-35
pubmed: 25441437
Minerva Urol Nephrol. 2021 Dec;73(6):739-745
pubmed: 32573170
Int J Urol. 2022 Apr;29(4):282-288
pubmed: 34973156
BJU Int. 2018 Apr;121(4):565-574
pubmed: 29032581
Eur Urol. 2010 Sep;58(3):340-5
pubmed: 20825756
Urology. 2019 Feb;124:160-167
pubmed: 30107186

Auteurs

Aldo Brassetti (A)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Giovanni E Cacciamani (GE)

USC Institute of Urology and Catherine, Joseph Aresty Department of Urology, Keck School of Medicine, Los Angeles, CA 90033, USA.

Andrea Mari (A)

Department of Experimental and Clinical Medicine, Oncologic Minimally Invasive Urology and Andrology Unit, Careggi Hospital, University of Florence, 50134 Florence, Italy.

Juan D Garisto (JD)

Department of Urology, Cleveland Clinic, Cleveland, OH 44195, USA.

Riccardo Bertolo (R)

Division of Urology, San Carlo di Nancy Hospital, 00165 Rome, Italy.

Chandru P Sundaram (CP)

Department of Urology, Indiana University, Indianapolis, IN 47405, USA.

Ithaar Derweesh (I)

Department of Urology, UCSD Health System, La Jolla, CA 92103, USA.

Ahmet Bindayi (A)

Department of Urology, UCSD Health System, La Jolla, CA 92103, USA.

Prokar Dasgupta (P)

MRC Centre for Transplantation, Guy's Hospital, King's College, London WC2R 2LS, UK.

James Porter (J)

Swedish Urology Group, Seattle, WA 98104, USA.

Alexander Mottrie (A)

Department of Urology, OLV Hospital, 9300 Aalst, Belgium.

Luigi Schips (L)

Department of Urology, Annunziata Hospital, G. D'Annunzio University, 66100 Chieti, Italy.

Koon Ho Rah (KH)

Urological Science Institute, Yonsei University College of Medicine, Seoul 03722, Korea.

David Y T Chen (DYT)

Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Chao Zhang (C)

Department of Urology, Changhai Hospital, Shanghai 200433, China.

Kenneth Jacobsohn (K)

Department of Urology, Medical College Wisconsin, Milwaukee, WA 53226, USA.

Umberto Anceschi (U)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Alfredo M Bove (AM)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Manuela Costantini (M)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Mariaconsiglia Ferriero (M)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Riccardo Mastroianni (R)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Leonardo Misuraca (L)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Gabriele Tuderti (G)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Alexander Kutikov (A)

Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Wesley M White (WM)

Department of Urology, University of Tennessee Medical Center, Knoxville, TN 37920, USA.

Stephen T Ryan (ST)

Department of Urology, UCSD Health System, La Jolla, CA 92103, USA.

Francesco Porpiglia (F)

Division of Urology, San Luigi Gonzaga Hospital, University of Turin, 10124 Orbassano, Italy.

Jihad Kaouk (J)

Department of Urology, Cleveland Clinic, Cleveland, OH 44195, USA.

Andrea Minervini (A)

Department of Experimental and Clinical Medicine, Oncologic Minimally Invasive Urology and Andrology Unit, Careggi Hospital, University of Florence, 50134 Florence, Italy.

Inderbir Gill (I)

USC Institute of Urology and Catherine, Joseph Aresty Department of Urology, Keck School of Medicine, Los Angeles, CA 90033, USA.

Riccardo Autorino (R)

Division of Urology, Department of Surgery, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.

Giuseppe Simone (G)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Classifications MeSH